

© 2011 Belgian Cancer Registry Stichting Kankerregister - Fondation Registre du Cancer – Stiftung Krebsregister

Staff at the Cancer Registry:
Kris Henau, Karen Vos, Martine Verstreken, Frédéric Calay, Greet Pieters,
Aline Kayumba, Linda Thibaut, Elke Van Vaerenbergh, Marie-José Hoovelts,
Kristel Van Damme, Christel Vervoort, Sophie Petit, Emilie Vandeghinste,
Mia Slabbaert, Annemie Haelens, Caroline Androgé, Jimmy Van den Eynden,
Céline Degaillier, Tamara Vandendael, Julie Francart, Cindy De Gendt, Koen Beirens,
Harlinde De Schutter, Jessica Van de Ven, Marielle Adam, Katia Emmerechts,

Editorial team: Kris Henau, Julie Francart, Karen Vos, Katia Emmerechts, Liesbet Van Eycken

Use of data

Recommended reference Cancer Incidence in Belgium, 2008, Belgian Cancer Registry, Brussels 2011

e-mail: info@kankerregister.org info@registreducancer.org

With financial support of:



























Acknowledgements We send our special thanks to

- Eero Pukkala and Toni Patama from the Finnish Cancer Registry who generously shared their methodology for mapping cancer incidence and created
- the chairmen and the members of the Executive Board and of the Scientific Advisory Board
- Françoise Renard for her persisting effort in the data gathering during the past years, her participation to this publication and for her appreciated expertise Nathalie De Wever and Paul Goddeeris for their fine collaboration and professional advice on pathology

CONTENTS

Forew	ord		5					
Sumn	narv		7					
Ju			······································					
1 Can	cer reg	gistration in Belgium: methodology	9					
1.1	The Belgian Cancer Registry 2005-2010							
1.2	Population and region							
1.3	Data	11						
	1.3.1	Notification and submission to the registry	11					
	1.3.2	Quality control and data linkage	12					
	1.3.3	Exclusion criteria and multiple tumours	12					
1.4	Use o	of cancer mortality data	13					
1.5	Quali	14						
1.6	Calcu	lation of incidence rates, risk and trends	18					
1.7	Марр	oing cancer incidence in Belgium	20					
2 Car	cer inc	cidence and mortality	23					
2.1	Cance	er of all sites	23					
2.2	Head	and neck (ICD-10: Coo-C14, C30-C32)	30					
2.3	Diges	Digestive tract						
	2.3.1	Oesophagus (ICD-10: C15)	36					
	2.3.2	Stomach (ICD-10: C16)	42					
	2.3.3	Colon and rectum (ICD-10: C18-C20)	47					
	2.3.4	Liver (ICD-10: C22)	53					
	2.3.5	Gallbladder and biliary tract (ICD-10: C23-C24)	58					
	2.3.6	Pancreas (ICD-10: C25)	63					
2.4	Respi	ratory tract	69					
	2.4.1	Lung (ICD-10: C34)	69					
	2.4.2	Mesothelioma (ICD-10: C45)	75					
2.5	Malig	gnant melanoma (ICD-10: C43)	78					
2.6	Breas	84						
2.7	Female genital organs							
	2.7.1	Cervix (ICD-10: C53)	90					
	2.7.2	Corpus uteri (ICD-10: C54)	94					
	2.7.3	Ovary (ICD-10: C56)	98					
2.8	Male	genital organs	103					
	2.8.1	Prostate (ICD-10: C61)	103					
	2.8.2	Testis (ICD-10: C62)	108					
2.9	Urina	ry tract	112					
	2.9.1	Kidney (ICD-10: C64)	112					
	2.9.2	Bladder (ICD-10: C67)	118					
2.10	Centr	ral nervous system (ICD-10: C71-C72)	123					
2.11	Thyro	oid (ICD-10: C73)	129					
3 Ref	erence	list	137					
4 AP	Jenaix	I	141					

Trends


Table 8 Invasive tumours (excl. non-melanoma): incidence and mortality by sex and region, 1999-2008

Invasive tumours (excl. non-melanoma): number of invasive tumours by sex and region, 1999-2008										
Males	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Belgium						32,417	32,269	31,844	32,354	32,508
Flemish Region	15,975	17,099	17,769	17,151	18,287	19,394	19,530	19,767	20,066	20,185
Brussels Capital Region						2,424	2,525	2,328	2,437	2,500
Walloon Region						10,599	10,214	9,749	9,851	9,823
Females	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Belgium						26,208	26,161	26,244	27,126	27,488
Flemish Region	12,838	13,766	14,263	14,112	14,728	14,957	15,253	15,230	15,832	15,906
Brussels Capital Region						2,518	2,435	2,526	2,541	2,567
Walloon Region						8,733	8,473	8,488	8,753	9,015
Invasive tumours (excl. no	n-melanoi	ma): age-	standardis	sed incide	nce (WSR) by sex a	nd region	, 1999-20	о8	
Males	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Belgium						368.8	362.9	354-3	355.6	350.3
Flemish Region	322.9	339.8	346.6	329.9	347.2	359.6	358.3	356.7	355-9	350.6
Brussels Capital Region						338.2	348.2	321.1	340.0	341.9
Walloon Region						394.0	374.7	357.1	357-9	350.9
Females	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Belgium						277.7	275.6	274.1	278.5	276.5
Flemish Region	245.5	260.1	268.2	259.8	268.7	268.4	271.7	269.9	274.6	269.3
Brussels Capital Region						294.7	283.8	298.2	292.8	289.8
Walloon Region						290.4	281.2	276.2	282.2	286.0


WSR: age-standardised rate, using the World Standard Population (n/100,000 person years)

Males	1999	2000	2001	2002	2003	2004	2005	2006	2007	200
Belgium						14,659	14,788			15,09
Flemish Region	8,906	8,886	8,755	8,782	8,749	8,570	8,782	8,828	8,806	8,99
Brussels Capital Region	1,314	1,281	1,252	1,265	1,185	1,167	1,198	1,159	1,123	1,17
Walloon Region						4,922	4,808			4,92
Females	1999	2000	2001	2002	2003	2004	2005	2006	2007	200
Belgium						11,034	10,912			11,55
Flemish Region	6,382	6,227	6,218	6,366	6,263	6,112	6,338	6,401	6,527	6,65
Brussels Capital Region	1,180	1,157	1,193	1,141	1,174	1,162	1,035	1,129	1,090	1,08
Walloon Region						3,760	3,539			3,81
Invasive tumours (excl. no	n-melano	ma): age-s	tandardi	sed morta	lity (WSR) by sex a	nd region	, 1999-200	8	
Males	1999	2000	2001	2002	2003	2004	2005	2006	2007	200
Belgium						153.0	151.0			144.
Flemish Region	169.0	164.9	159.3	156.5	152.4	146.4	146.1	143.3	139.4	139.
Brussels Capital Region	171.8	164.7	160.0	160.1	154.7	150.5	151.8	142.9	138.3	141
Walloon Region						166.6	160.9			155.
Females	1999	2000	2001	2002	2003	2004	2005	2006	2007	200
Belgium						87.4	85.8			85.
Flemish Region	93.8	90.7	89.7	90.1	86.1	83.7	85.6	84.5	85.1	84
							00.0	_		
Brussels Capital Region	96.4	98.7	100.9	95.5	102.3	94.1	88.8	96.7	91.8	90

WSR: age-standardised rate, using the World Standard Population (n/100,000 person years)



- In the Flemish Region, a yearly increase of about 1% in age-standardised incidence rates in males and females is observed between 1999 and 2008 (males: EAPC = 0.9% [p = 0.01], females: EAPC = 0.8% [p = 0.01]).
- In the same period, mortality in the Flemish Region decreases in males (EAPC = -2.2% [p = 0.00]) and females (EAPC = 1.1% [p = 0.00]).
- A similar trend is observed for mortality in the Brussels Capital Region (males: EAPC = 2.2% [p = 0.00], females: EAPC = -1.0% [p = 0.05]).
- The decrease in incidence in the Walloon Region is partly explained by the inclusion of prevalent cases in the first registration years. This is a known and common phenomenon in the start-up phase of a cancer registry⁽³⁷⁾.



- Under the age of 30 years (data not shown), the incidence rates between males and females are comparable (male/female ratio is 1.1).
- In the age group 30-49 years, the incidence rate in females is 2 times higher than the incidence rate in males.
 - No regional differences are observed.
 - In the Flemish Region, a significant increase is observed in females (EAPC = 1.1% [p = 0.02]), while the rate in males remains more stable (EAPC = 0.5% [p = 0.31]).
- In the age group 50-64 years, the male/female incidence ratio is 1.2.
 - No regional differences are observed.
 - In the Flemish Region, an increasing trend is observed in males (EAPC = 1.7% [p = 0.00]). No significant trend is observed in females (EAPC = 0.4% [p = 0.34]).
 - The incidence is 7 times higher than in the age group 30-49 years in males and 3 times higher in females.
- In the age group 65 years and older, the incidence rates in males is 2 times higher than in females.
 - The incidence rate in males is higher in the Flemish Region when compared to the other regions.
 - In the Flemish Region, a significant increase is observed in females (EAPC = 1.3% [p = 0.00]). In males, no significant trend is observed (EAPC = 0.4% [p = 0.24]).
 - The incidence is 2.6 times higher than in the age group 50-64 years in males and 1.6 times higher in females.
 - When compared to the age group 30-49 years, the incidence rate in males in the age group 65 years and older is 19 times higher, in females the incidence rate is 5 times higher.